NKTR
Nektar Therapeutics
NASDAQ · USHealthcareBiotechnology
$64.84-5.01%
Price as of Jul 20, 2026
NKTR profitability
Nektar Therapeutics profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 99.4%
- EBITDA margin
- -226.4%
- EBIT margin
- -224.9%
- Net margin
- -284.2%
- Free cash flow margin
- -366.6%
Returns
- Return on equity
- -27.4%
- Return on assets
- -20.7%
- Return on invested capital
- -17.4%
- Asset turnover
- 0.11x
Cash efficiency
- Cash from operations
- -$203.8M
- Cash per share
- $17
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.